Evidence map›Paper›PMID 37671156›Full record

ReviewFrontiers in immunology2023

Controlling viral inflammatory lesions by rebalancing immune response patterns.

Sachin Mulik, Engin Berber, Sharvan Sehrawat, Barry Tyrrell Rouse

Open access · goldAbstract readReview
In one paragraph

Review in Frontiers in immunology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.0field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Review
  6. Article
  7. Review
  8. Meeting the Challenge of Controlling Viral Immunopathology.International journal of molecular sciences · 2024
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 4 institutions in 2 countries.

Sachin MulikCenter for Biomedical Research, The University of Texas Health Science Center at Tyler, Tyler, TX, United States.
Engin BerberInfection Biology, Lerner Research Institute, Cleveland Clinic, Cleveland, OH, United States.
Sharvan SehrawatIndian Institute of Science Education and Research, Department of Biological Sciences, Mohali, Punjab, India.
Barry Tyrrell RouseCollege of Veterinary Medicine, University of Tennessee, Knoxville, TN, United States.
Cleveland Clinic Lerner College of Medicine · USIndian Institute of Science Education and Research Mohali · INThe University of Texas Health Science Center at Tyler · USUniversity of Tennessee at Knoxville · US

Funding

Mechanisms of Herpetic KeratitisR01EY005093 · NEI · UNIVERSITY OF TENNESSEE KNOXVILLE · PI ROUSE, BARRY T. · 1985 to 2020
$7.8M
IMMUNITY MECHANISMS IN HERPESVIRUS INFECTIONSR01AI014981 · NIAID · UNIVERSITY OF TENNESSEE KNOXVILLE · PI ROUSE, BARRY T. · 1985 to 2005
$1.7M
NEI NIH HHS R01 EY005093NIAID NIH HHS R01 AI014981
6 · The paper itself

Abstract

In this review, we discuss a variety of immune modulating approaches that could be used to counteract tissue-damaging viral immunoinflammatory lesions which typify many chronic viral infections. We make the point that in several viral infections the lesions can be largely the result of one or more aspects of the host response mediating the cell and tissue damage rather than the virus itself being directly responsible. However, within the reactive inflammatory lesions along with the pro-inflammatory participants there are also other aspects of the host response that may be acting to constrain the activity of the damaging components and are contributing to resolution. This scenario should provide the prospect of rebalancing the contributions of different host responses and hence diminish or even fully control the virus-induced lesions. We identify several aspects of the host reactions that influence the pattern of immune responsiveness and describe approaches that have been used successfully, mainly in model systems, to modulate the activity of damaging participants and which has led to lesion control. We emphasize examples where such therapies are, or could be, translated for practical use in the clinic to control inflammatory lesions caused by viral infections.

Indexed as

Models, BiologicalPyrimethamineHumansSulfadiazinePyrimethamineSulfadiazineimmune exhaustionimmune regulationimmunometabolismimmunopathologyimmunotherapymicroRNAviral pathogenesis

Identifiers

PMID37671156
PMCPMC10475736
OpenAlexW4386026743

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.